Japan Faces “Worst

News Highlights

A surge in naphtha prices poses a risk of widespread bankruptcies across the Japanese economy. Medical institutions, in particular, are facing a situation where rising procurement costs for items like injectable drugs mean they “lose money the more they administer injections,” raising serious concerns about the impact on management. Specific figures, such as a 26% increase in bankruptcies within the painting industry, highlight that a broad range of sectors are facing a crisis.

M&A Medical Editorial Department’s Perspective

The Daily Shincho article succinctly points to the potential impact of soaring naphtha prices on the management of medical institutions. The phrase “lose money the more they administer injections” evokes a scenario where the procurement costs for pharmaceuticals and medical supplies easily exceed any revenue increases from medical fee revisions. This cost increase could fundamentally shake the management of small to medium-sized hospitals and clinics, especially those that are community-based and find it difficult to make large capital investments or expand their workforce. For instance, if a medium-sized hospital in a certain region, primarily focused on surgical procedures, experiences a 15% increase in the procurement price of surgical consumables and anesthetics, it could result in additional annual costs amounting to tens of millions of yen. Such a situation could become a threat to the very continuity of business, not just a temporary decline in performance. Business succession through M&A, whether before falling into such management difficulties or after they have occurred, becomes a realistic option for maintaining patient and staff employment and keeping the lights of regional healthcare services on. Identifying early warning signs of deteriorating financial conditions and collaborating with experts to consider succession schemes can lead to more favorable terms for transfer or stable post-succession operations.

Points Raised by This News

• The possibility that increased procurement costs in medical institutions could become a deficit factor exceeding medical fees.
• The risk that soaring naphtha prices could affect the entire supply chain for pharmaceuticals and medical supplies.
• Concerns that the financial resilience of small and medium-sized hospitals and clinics supporting regional healthcare will be further weakened by cost increases.
• The potential for deteriorating medical profit margins to directly lead to the “worst-case scenario” in hospital management.

Practical Questions Arising from This News

• Specifically, which pharmaceuticals and medical supplies are likely to see cost increases, and by how much?
• To what extent can the red ink from increased procurement costs be covered by medical fee revisions or other services?
• In this situation, what is the optimal timing to consider business succession through M&A?

If You Feel “Should I Consult?”

If your institution is experiencing a noticeable rise in procurement prices for pharmaceuticals and medical supplies, a sustained decline in medical profit margins, or an uncertain future outlook, it is a sign that you should consult with an expert promptly. Naphtha price trends may continue to bring uncertainty to the management of medical institutions. Business succession through M&A can be an effective option to protect the future of patients and staff, under better terms, before management difficulties become severe. We recommend first accurately assessing your current financial situation and then discussing future risks and countermeasures with an expert. M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are handled with strict confidentiality. Free consultations are available here.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are handled with strict confidentiality. Free consultation here